Keyword: Genentech

Nektar Therapeutics poached Genentech immunotherapy leader Wei Lin to head up its oncology program and serve as VP of clinical development.

Intellia clinical head to be Casebia’s first CMO; Ferring CSO to take over for retiring board president; and Harpoon names new CFO and CSO.

Four of Genentech’s former U.S. researchers are accused of passing information to a foreign rival developing biosimilars of its top drugs.

Affimed has halted work on trials of its lead T cell engager AFM11 for blood cancers after a death and two life-threatening events.

An engineered form of a naturally occurring molecule can penetrate hard-to-kill, Gram-negative bacteria.

Arvinas has filed to raise up to $100 million in its IPO to get its lead assets through the IND stage and into phase 1.

The deal features $5 billion in milestones and royalties that could land in Affimed’s bank account if the immunotherapies succeed.

The FDA cleared Roche’s cobas EGFR test for use as a companion diagnostic for AstraZeneca’s Iressa in first-line non-small cell lung cancer.

Tolero Pharmaceuticals has inked a pact to test its CDK9 inhibitor, alvocidib, in combination with AbbVie’s Venclexta in relapsed/refractory AML.

Genentech’s refillable eye implant showed positive results in a phase 2 wet AMD study, allowing patients to skip monthly Lucentis injections.